Raglan Capital was established ten years ago as a full-service corporate finance boutique and very quickly established its reputation as a leading and successful business.

However, in the last couple of years, Raglan has ceased providing any third party corporate finance services as it is now solely focused upon creating its own new companies that can be rapidly listed on the London stock exchange with the general target being to complete an IPO within two to three years’ post inception. In the past 24 months, Raglan established Amryt Pharma Plc which is now listed on both the London and Dublin stock exchanges and has a market cap in excess of £50m and is now an established European orphan drug company. Amryt already has rapidly growing monthly sales revenues of c. a million euro, while at the same time managing a pipeline of drugs in development including its potential blockbuster EB orphan drug now in its final FDA phase three trials. Prior to that Raglan established Fastnet Oil & Gas plc which floated on the London and Dublin stock exchanges raising over $50m. T5 Oil & Gas is another Raglan creation with high hopes of completing its IPO in 2017 hopefully followed by a second successful life science IPO early in 2018.

The team behind Raglan Capital have many years of deal making experience with a proven track record of achieving exceptional results.

With offices in Dublin, London and Vienna, our relationships include regular contact with investment banks, private equity firms and a broad range of investors which provides Raglan Capital with invaluable access to local advisers and contacts when completing international transactions.